Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522651 | 0.84 | TRPV3 (0.45) | TRPV3GAAKCNH2ALOX5APFFAR4 | |
| SCHEMBL31445247 | 0.79 | HTR7 (0.43) | HTR7HTR1ADRD2 | |
| SCHEMBL2306499 | 0.79 | HTR7 (0.43) | HTR7HTR1ADRD2 | |
| SCHEMBL17036733 | 0.79 | TRPV3 (0.40) | TRPV3KCNH2ALOX5APFFAR4 | |
| SCHEMBL16472623 | 0.78 | HTR7 (0.41) | HTR7TRPV3IRAK4 | |
| SCHEMBL6964 | 0.78 | — | — | |
| SCHEMBL29427033 | 0.78 | — | — | |
| SCHEMBL14545220 | 0.77 | CCR1 (0.44) | TRPV3KCNH2ALOX5AP | |
| SCHEMBL24015238 | 0.76 | HTR7 (0.45) | HTR7IRAK4HTR1ADRD2HTR2A | |
| SCHEMBL22550725 | 0.75 | TRPV3 (0.40) | TRPV3KCNH2ALOX5APFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104496891-A | Synthesis method of pyridine derivative 2-tert-butoxy-6-methylene chloropyridine | HARBIN INST OF TECHNOLOGY | 2015-04-08 | — | — | CN | claimed |
| CN-118271299-A | Lactam compound, and preparation method and application thereof | 广州市联瑞制药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2021145401-A1 | SPIROHETEROCYCLIC DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-07-22 | — | — | WO | disclosed |
| US-9624182-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-2483252-B1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9090573-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| CN-104496891-A | Synthesis method of pyridine derivative 2-tert-butoxy-6-methylene chloropyridine | HARBIN INST OF TECHNOLOGY | 2015-04-08 | — | — | CN | disclosed |
| CN-104496891-A | Synthesis method of pyridine derivative 2-tert-butoxy-6-methylene chloropyridine | HARBIN INST OF TECHNOLOGY | 2015-04-08 | — | — | CN | disclosed |
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. | 2012-11-15 | — | — | US | disclosed |
| EP-2057109-A2 | ADDITION REACTIONS USING TRANSITION METAL CATALYSTS IN HALOGENATED SOLVENTS | BASF SE (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008046918-A2 | ADDITION REACTIONS USING TRANSITION METAL CATALYSTS IN HALOGENATED SOLVENTS | BASF SE (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | HTR7 409/4885TRPV3 350/4885GAA 1192/4885 |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | HTR7 409/4885TRPV3 350/4885GAA 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.